▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1070 by analyst upside · 2026-09-09
ENGN
enGene Therapeutics Inc.
Healthcare · Market Cap $129M · P/E 0x
ANALYST PRICE TARGET
+71.1%
implied upside to consensus target
Current Price $1.92
Consensus Target $3.29
Bull Target $5.0
Bear Target $2.0
Analysts Covering 7
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
1
Hold
4
Sell
1
52-Week Low $1.4
52-Week High $12.25
YTD Return -78.3%
FUNDAMENTALS
Market Cap $129M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.19
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.4
52-Week High $12.25
Current Price $1.92
Bear Target $2.0
Bull Target $5.0
● Now $1.92 ● Target $3.29
TRADING DATA
Avg Volume 881K
YTD Return -78.3%
Analyst Count 7
Consensus Hold
Upside to Target +71.1%
Last Updated 2026-09-09

ANALYST SUMMARY

enGene Therapeutics Inc. (ENGN) is currently trading at $1.92 with a Wall Street consensus price target of $3.29, implying potential upside of 71.1% over the next 12 months. 7 analysts currently cover ENGN, with a consensus rating of Hold - 29% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $5.0, while the most cautious has a target of $2.0.

ENGN operates in the Healthcare sector with a market capitalisation of $129M. The stock is down 78.3% year-to-date and is currently trading near the lower end of its 52-week range of $1.4 – $12.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

WW +57.5%
WW International, Inc.
$180M · P/E 1.6x · Hold
OPRX +63.2%
OptimizeRx Corporation
$143M · P/E 30.4x · Buy
ORMP +40.6%
Oramed Pharmaceuticals Inc.
$207M · P/E 1.2x · Hold
BSEM +75.0%
BioStem Technologies, Inc.
$71M · P/E 4.5x · Buy
CGEN +79.7%
Compugen Ltd.
$242M · P/E 6.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ENGN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley ↓ Downgrade
Equal-Weight → Underweight 2026-06-18 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-16 31% win rate (48 calls)
UBS - Reiterated
Neutral → Neutral 2026-05-14 33% win rate (6 calls)
Citizens ↓ Downgrade
Market Outperform → Market Perform 2026-05-08 Building track record
Guggenheim ↓ Downgrade
Buy → Neutral 2026-05-08 62% win rate (8 calls)
Wells Fargo ↓ Downgrade
Overweight → Equal-Weight 2026-05-08 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-08 31% win rate (48 calls)
Piper Sandler ↓ Downgrade
Overweight → Neutral 2026-05-08 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
18
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →